Longevity · FDA Approved
Gonadotropin Releasing Hormone (GnRH) Agonists
FDA-approved
01 · Overview
Gonadotropin-releasing hormone agonists are synthetic analogues of native GnRH that initially stimulate and then, with continuous exposure, downregulate pituitary receptors and reversibly suppress the hypothalamic-pituitary-gonadal axis, reducing sex steroid production. Approved agents include leuprolide, goserelin and triptorelin, listed as prescription products in FDA drug approval records and used in hormone-sensitive cancers and reproductive medicine.
All of the commonly used agonists have comparable ability to suppress testosterone in men with prostate cancer (PMID 35343198). The longevity rationale rests on theoretical models linking reduced reproductive signaling to lifespan in model organisms and remains speculative in humans.
02 · Research summary & key findings
Androgen deprivation therapy using GnRH agonists remains the backbone of advanced prostate cancer treatment, with goserelin, triptorelin, buserelin, histrelin and leuprorelin showing comparable testosterone suppression (PMID 35343198). Long-term androgen deprivation therapy is associated with decreased bone mineral density in men with prostate cancer, although some evidence suggests the fracture consequences are less clear (PMID 33577365). No prospective trials testing GnRH suppression for human longevity were identified, so the longevity rationale remains hypothetical.
03 · Regulatory status
Gonadotropin Releasing Hormone (GnRH) Agonists has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Gonadotropin Releasing Hormone (GnRH) Agonists is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
Gonadotropin Releasing Hormone (GnRH) Agonists is prescribed for the conditions on its label, and it is not part of our intake. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
- Intramuscular injection
- Subcutaneous implant
- Intranasal
References
- [1]The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients J Urol, 2021. PMID 33577365
- [2]Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety Indian J Cancer, 2022. PMID 35343198
Primary literature
- PubMed: "Gonadotropin Releasing Hormone Agonists"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Gonadotropin Releasing Hormone Agonists"
Registered interventional and observational studies, including status and phase.
- PubChem: "Gonadotropin Releasing Hormone Agonists"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Longevity
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.